The New Dawn in Bladder Cancer: EV-302 and the End of the “Chemo-Only” Era
The New Dawn in Bladder Cancer: EV-302 and the End of the “Chemo-Only” Era In a Nutshell: The standard of care for advanced urothelial cancer has remained stagnant for decades—until now. The combination of Enfortumab Vedotin and Pembrolizumab is nearly doubling survival rates, fundamentally rewriting the NHS treatment pathway.
